Chuck Norris sues gadolinium manufacturers, claims wife was poisoned

Melissa Rohman | | Health Imaging | Cardiac Imaging

Acclaimed action star Chuck Norris filed a lawsuit Wednesday, Nov. 1, alleging gadolinium from MRI imaging scans has poisoned his wife, Gena, and is seeking more than $10 million in damages to cover her medical expenses. The suit names several manufacturers of gadolinium contrast agents.

According to a recent article from The Washington Post, the lawsuit states that Norris' wife has been left feeling week and tired with "debilitating bouts of pain and a burning sensation" due to gadolinium usage to improve clarity of her MRI scans. 

“One of the problems is this is a very misdiagnosed and underdiagnosed condition,” said Todd Walburg, an attorney for the Norris family. 

For more information, see the orginal article here.  

Chuck Norris sues over MRI chemical he says poisoned wife

""
Melissa Rohman

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Related Content

New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD
New AI program delivers rapid, accurate echo video assessments
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage
New scoring system accurately predicts coronary risk in women

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.